• This topic is empty.
Viewing 0 reply threads
  • Author
    Posts
    • #21406
      Duane
      Participant

      Findings  In this multicenter, propensity score–matched cohort study of 324 patients with ALS, long-term intravenous edaravone treatment was feasible and was mainly well tolerated. However, disease progression rates, time to noninvasive ventilation, and survival probability did not significantly differ from matched patients with ALS receiving only standard therapy.

      Meaning  These findings show that reatment with long-term intravenous edaravone in addition to standard therapy for patients with ALS is feasible and relatively safe but may not provide a clinically relevant benefit.

      https://jamanetwork.com/journals/jamaneurology/article-abstract/2787473

      <span class=”meta-citation-journal-name”>JAMA Neurol. </span><span class=”meta-citation”>Published online January 10, 2022. doi:10.1001/jamaneurol.2021.4893</span>

Viewing 0 reply threads
  • You must be logged in to reply to this topic.

©2022 KLEO Template a premium and multipurpose theme from Seventh Queen

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account